Morgan Stanley Issues Pessimistic Forecast for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) had its price objective reduced by analysts at Morgan Stanley from $755.00 to $754.00 in a research report issued on Thursday,Benzinga reports. The brokerage presently has an "overweight" rating on the biopharmaceutical company's stock. Morgan Stanley's target price indicates a potential upside of 32.81% from the company's current price.

Other research analysts also recently issued research reports about the stock. Argus downgraded shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Monday, June 30th. Royal Bank Of Canada downgraded shares of Regeneron Pharmaceuticals from a "moderate buy" rating to a "hold" rating and set a $662.00 price objective on the stock. in a research report on Friday, May 30th. Robert W. Baird cut their price objective on shares of Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating on the stock in a research report on Friday, April 25th. Bank of America cut their price objective on shares of Regeneron Pharmaceuticals from $575.00 to $547.00 and set an "underperform" rating on the stock in a research report on Thursday, April 17th. Finally, Guggenheim reaffirmed a "buy" rating on shares of Regeneron Pharmaceuticals in a research report on Friday, May 30th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, sixteen have issued a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $823.54.

Regeneron Pharmaceuticals Stock Up 1.4%

NASDAQ REGN traded up $7.98 during trading on Thursday, reaching $567.74. 844,505 shares of the company's stock traded hands, compared to its average volume of 917,464. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.93 and a quick ratio of 4.03. The firm has a market cap of $61.29 billion, a price-to-earnings ratio of 14.45, a price-to-earnings-growth ratio of 2.11 and a beta of 0.33. The company's 50 day simple moving average is $545.22 and its two-hundred day simple moving average is $619.17. Regeneron Pharmaceuticals has a 12-month low of $476.49 and a 12-month high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). The business had revenue of $3.03 billion for the quarter, compared to analysts' expectations of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.94% and a return on equity of 15.27%. The company's revenue for the quarter was down 3.7% on a year-over-year basis. During the same period last year, the business posted $9.55 EPS. As a group, sell-side analysts forecast that Regeneron Pharmaceuticals will post 35.92 EPS for the current fiscal year.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Several large investors have recently made changes to their positions in the company. Vanguard Group Inc. lifted its stake in shares of Regeneron Pharmaceuticals by 1.3% in the 1st quarter. Vanguard Group Inc. now owns 9,407,891 shares of the biopharmaceutical company's stock valued at $5,966,767,000 after purchasing an additional 121,545 shares during the period. Capital International Investors lifted its stake in shares of Regeneron Pharmaceuticals by 41.6% in the 4th quarter. Capital International Investors now owns 4,736,929 shares of the biopharmaceutical company's stock valued at $3,373,859,000 after purchasing an additional 1,390,534 shares during the period. Geode Capital Management LLC lifted its stake in shares of Regeneron Pharmaceuticals by 6.8% in the 4th quarter. Geode Capital Management LLC now owns 2,427,630 shares of the biopharmaceutical company's stock valued at $1,726,940,000 after purchasing an additional 155,369 shares during the period. Dodge & Cox lifted its stake in shares of Regeneron Pharmaceuticals by 0.4% in the 4th quarter. Dodge & Cox now owns 2,321,316 shares of the biopharmaceutical company's stock valued at $1,653,543,000 after purchasing an additional 9,381 shares during the period. Finally, Price T Rowe Associates Inc. MD lifted its stake in shares of Regeneron Pharmaceuticals by 4.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,175,026 shares of the biopharmaceutical company's stock valued at $1,379,467,000 after purchasing an additional 89,579 shares during the period. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.